Screener
Bicara Therapeutics BCAX Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (60,242) | (41,788) |
| Other income | ||
| Interest income | 4,083 | 5,014 |
| Total other income | 4,083 | 5,014 |
| Net loss before income taxes | (56,159) | (36,774) |
| Income tax expense | (52) | (72) |
| Net loss | $(56,211) | $(36,846) |
| Net Loss per share, basic and diluted | $(0.93) | $(0.68) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's other income (expense)?
- Bicara Therapeutics (BCAX) reported other income (expense) of $4.08M in Q1 2026.
- How has Bicara Therapeutics's other income (expense) changed year-over-year?
- Bicara Therapeutics's other income (expense) decreased by 18.6% year-over-year, from $5.01M to $4.08M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Bicara Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude